A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795

NCT04844450 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Fatty Liver Disease

Interventions

DRUG: JNJ-75220795
DRUG: Placebo

Sponsor

Janssen Research & Development, LLC